H. W. Rogers, N. A. Weinstock, A. R. Harris, M. R. Hinckley, S. R. Feldman, A. B. Fleischer and B. M. Coldiron, “Incidence Estimate of Nonmelanoma Skin Cancer in the United States,” Archives of Dermatology, Vol. 146, No. 3, 2010, pp. 283-287. doi:10.1001/archdermatol.2010.19

has been cited by the following article:

• TITLE: Topical Solasodine Rhamnosyl Glycosides Derived From the Eggplant Treats Large Skin Cancers: Two Case Reports

  AUTHORS: Bill E. Cham

  KEYWORDS: Nonmelanoma Skin Cancers, Solasodine Rhamnosyl Glycosides, Curaderm, Solamargine, Solasonine

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.2 No.4, September 30, 2011

  ABSTRACT: Solasodine rhamnosyl glycosides (BEC) are a new class of antineoplastics that show superior efficacy than many established anticancer drugs as shown by intravenous, intraperitoneal and intralesion administrations. Previous studies have described the efficacy of BEC on nonmelanoma skin cancers by topical application. Two cases are now reported which show that BEC in a cream formulation Curaderm is very effective for the treatment of large nonmelanoma skin cancers that are considered difficult to treat by existing modalities. Moreover, the cosmetic outcomes are very impressive.